PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast-logo

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Education Podcasts

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Location:

United States

Description:

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Language:

English


Episodes

Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

6/18/2021
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale,...

Duration:00:27:04

Karl E. Anderson, MD - Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy

6/2/2021
Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be...

Duration:00:31:56

Dara L. Aisner, MD, PhD / Joshua Bauml, MD / Paul A. VanderLaan, MD, PhD - Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC

6/1/2021
Go online to PeerView.com/KQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with non–small cell lung cancer (NSCLC) is exemplary of precision medicine. Extensive and nuanced genomic profiling of NSCLC is essential to inform individualized treatment plans to optimize patient outcomes. Currently, there are seven different molecular alterations for which FDA-approved targeted therapies are available: EGFR, ALK,...

Duration:01:07:32

Naval Daver, MD - Optimizing Care for High-Risk Myeloid Cancers: Interprofessional Team Insights From a Center of Excellence

5/28/2021
Go online to PeerView.com/BFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC/CC/NCPD-accredited activity, a hematologist-oncologist, a pathologist, and a physician assistant team up to discuss a collaborative approach to managing their patients with high-risk myeloid cancers, such as acute myeloid leukemia and myelodysplastic syndrome. Hear how Naval Daver, MD, Sanam Loghavi, MD, and Megan Wiese, PA-C, from the MD...

Duration:00:54:03

John M. Pagel, MD, PhD / Ian W. Flinn, MD, Ph - DConversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine

5/14/2021
Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts...

Duration:00:35:24

"Corey Cutler, MD, MPH, FRCP(C) & Miguel-Angel Perales, MD - New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment With Novel Therapeutics"

4/8/2021
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should...

Duration:00:53:18

Titte R. Srinivas, MD, FAST - Optimizing Maintenance Immunosuppressive Therapy in Kidney Transplantation: Examining Current and Future Strategies to Preserve Graft Function and Maximize Long-Term Outcomes

4/1/2021
Go online to PeerView.com/SDN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses evidence-based strategies to individualize immunosuppressive therapy and optimize long-term outcomes after renal transplantation. Upon completion of this activity, participants should be better able to: Identify risk factors for graft loss and mortality after renal transplantation, Recognize the benefits and...

Duration:00:28:16

Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

3/31/2021
Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon...

Duration:00:59:56

Ruben A. Mesa, MD, FACP / Jeanne M. Palmer, MD - How to Manage JAK Inhibition in Patients Undergoing HCT: Applying the Latest Clinical Evidence to Improve Patient Outcomes in Myelofibrosis

3/26/2021
Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment...

Duration:00:58:10

Stella Lee, MD - Improving the Management of Chronic Rhinosinusitis With Nasal Polyps: Practical Strategies for Selecting the Right Patients for Targeted Treatment

3/24/2021
Go online to PeerView.com/ERM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps (CRS/NP) discusses how to diagnose and manage CRS/NP; identifies patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy; and discusses treatment plans for patients with CRS/NP according to international consensus statements and the latest...

Duration:00:34:38

Jason J. Luke, MD, FACP - Expanding the Benefits of Immuno-Oncology to More Patients With Solid Tumors Through Novel Rational Targets and Combinations

3/22/2021
Go online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical...

Duration:00:39:00

Stephen V. Liu, MD - Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes

3/10/2021
Go online to PeerView.com/MSE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts...

Duration:01:03:09

Robert Z. Orlowski, MD, PhD / Nina Shah, MD - The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT

3/8/2021
Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with...

Duration:00:59:31

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Mapping the New Era in CLL Management: Precision Medicine and Patient Perspectives in Treatment-Naïve and Relapsed Disease

1/29/2021
Go online to PeerView.com/QUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologists, oncologists, and a patient advocate discuss compelling, real-world case scenarios and the practice-changing evidence that continues to support the increasing role of novel therapeutics in CLL. This event also explores the future of CLL care and illustrates how novel combinations and cellular therapy may lead...

Duration:01:36:51

Steven M. Horwitz, MD - Precision Medicine in Hematologic Cancers: Lessons for Diagnostic and Treatment Protocols in CD30- and CD123-Expressing Disease

1/22/2021
Go online to PeerView.com/FSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As precision medicine has taken a varying course in the setting of hematologic cancers, safely integrating effective, novel therapeutics into the management of patients whose cancers express markers such as CD30 and CD123 is more important than ever. In this activity, our experts discuss the diagnostic and treatment implications of these markers in various...

Duration:01:32:20

Jonathan Corren, MD - Reducing the Burden of Chronic Rhinosinusitis With Nasal Polyps on Patient Quality of Life: An Exploration of Novel and Emerging Biologic Therapy

1/12/2021
Go online to PeerView.com/XNY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps discusses novel and emerging biologic therapies to improve the quality of life for patients with chronic rhinosinusitis with nasal polyps. Upon completion of this activity, participants should be better able to: Recognize the burden that chronic rhinosinusitis with nasal polyps (CRS/NP) on...

Duration:00:30:42

Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

1/11/2021
Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time,...

Duration:01:01:53

Steven Fishbane, MD / Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN - HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?

1/8/2021
Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia,...

Duration:01:19:17

Nathan H. Fowler, MD - Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL

1/8/2021
Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval...

Duration:01:25:11

Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath - Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

1/8/2021
Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this...

Duration:01:34:02